2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
427
Magnetic Resonance Spectroscopy
338
pembrolizumab
262
Biopsy
230
Carboplatin
216
Cisplatin
180
Cyclophosphamide
174
Paclitaxel
148
Nivolumab
136
Gemcitabine
130
Radiotherapy
125
Dexamethasone
105
Bevacizumab
103
Radiation
97
fludarabine
95
Fluorouracil
93
Doxorubicin
90
Pemetrexed
88
Docetaxel
85
Rituximab
83
durvalumab
82
venetoclax
81
Oxaliplatin
81
Leucovorin
76
atezolizumab
70
Prednisone
66
Lenalidomide
66
Capecitabine
66
Etoposide
64
Vincristine
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
trilaciclib
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled